Committed to Helping You Get Your Genentech Medicine
Knowing what to expect can make all the difference. We can help walk
you through each step of getting your Genentech medicine and assist
you along the way.
Frequently Asked Questions
About HEMLIBRA Access Solutions
What is HEMLIBRA Access Solutions?
HEMLIBRA Access Solutions is a resource for people who take a
Genentech medicine. We connect you to the medicine you need.
I Am Concerned About Paying for HEMLIBRA
My co-pays for HEMLIBRA are too high. How can you help me?
There may be options to help you get the Genentech medicine your doctor has prescribed. HEMLIBRA Access Solutions can refer you to patient assistance options.
Getting My Medicine
Can I pick up my Genentech medicine from my local pharmacy?
You can’t get your Genentech medicine from your local pharmacy. Instead, it will come to you from a specialty pharmacy or treatment center pharmacy.
Your specialty pharmacy or treatment center pharmacy is different from your regular mail-order pharmacy. It handles drugs like HEMLIBRA.
When we check your coverage, we also refer you to a specialty pharmacy or treatment center pharmacy your health insurance plan will cover.
How long will it take to get my medicine?
You might not be able to get your Genentech medicine right away. First, your doctor’s office, specialty pharmacy, treatment center pharmacy or hospital pharmacy will have to check to make sure your health insurance plan covers your medicine. This is called a “benefits investigation.” They also might have to send some more information before your plan covers your medicine. This is called a “prior authorization.”
Enrolling in HEMLIBRA Access Solutions
How do I enroll in HEMLIBRA Access Solutions?
- You fill out a form called the PAN.
- Your doctor fills out a form called the SMN. You do not have to fill out anything on this form.
- Your doctor sends both of these forms to HEMLIBRA Access Solutions.
There are 2 ways to fill out the PAN form:
- You can fill out the form online
- You can download and print it to fill out a paper copy
Why do I need to sign the PAN form?
The PAN form lets us discuss your health information with your doctor
and your health insurance plan. We can’t work with you without a
I submitted the PAN online or gave the signed PAN to my doctor. Is there anything else I need to do to enroll?
You do not need to do anything else, but your doctor does. He or she needs to submit a form called the SMN. The SMN tells us your doctor wants to treat you with HEMLIBRA. Make sure your doctor has sent us the SMN so you get help from us.
You do not need to fill out anything on the SMN form.
My Health Plan Denied Coverage for HEMLIBRA
My health insurance plan will not cover HEMLIBRA. What do I do?
If your health insurance plan will not cover your Genentech medicine,
you and your doctor’s office can file an appeal. Contact your doctor
to find out if filing an appeal is right for you.
We have resources to help you and your doctor file an appeal.
Does HEMLIBRA Access Solutions send the appeal to my health insurance plan?
We have resources to help you and your doctor file an appeal. You or
your doctor’s office has to file the appeal directly with your health
How long does an appeal take?
This depends on your health insurance plan. You should ask your plan directly about its process. Sometimes the appeals process is quick. However, it can also take several months if you have to appeal several times.
My Insurance Might Change
I am enrolled in HEMLIBRA Access Solutions and my health insurance plan has changed. What do I do next?
If your insurance changes while you’re taking your Genentech
medicine, call us. We can help you understand your new coverage.
I no longer have a health insurance plan. What should I do?
GATCF helps people who don't have health insurance. It also helps
people who have health insurance but have trouble paying for their
Genentech medicine. If you qualify for GATCF, you could receive your
medicine for free.
It is your and your doctor's responsibility to complete and submit
all required paperwork to your health insurance plan. Genentech
cannot guarantee your plan will cover any treatments.
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
What it Treats
What is HEMLIBRA?
HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors.
Important Safety Information
What is the most important information I should know about HEMLIBRA?
HEMLIBRA increases the potential for your blood to clot. Discontinue prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent, and the dose and schedule you should use. HEMLIBRA may cause the following serious side effects when used with aPCC (FEIBA®), including:
- Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
- swelling of arms and legs
- yellowing of skin and eyes
- stomach (abdomen) or back pain
- nausea or vomiting
- feeling sick
- decreased urination
- Blood clots (thrombotic events). Blood clots may form in blood vessels in your arm, leg, lung or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
- swelling in arms or legs
- pain or redness in your arms or legs
- shortness of breath
- chest pain or tightness
- fast heart rate
- cough up blood
- feel faint
- numbness in your face
- eye pain or swelling
- trouble seeing
If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.
Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:
- are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.
- are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I use HEMLIBRA?
See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.
HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.
What are the other possible side effects of HEMLIBRA?
The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain.
These are not all of the possible side effects of HEMLIBRA. Call your doctor for medical advice about side effects.
General information about the safe and effective use of HEMLIBRA.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about HEMLIBRA that is written for health professionals.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.